Generic drugmaker Viatris has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sanofi's ...
After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry. Yet, their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results